Previous 10 | Next 10 |
SEATTLE, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, with an initial focus on life-threatening respiratory diseases and a visi...
2023-08-20 12:00:00 ET Ahead of the world's first immunization drive against respiratory syncytial virus (RSV), a new report from the London-based health analytics firm Airfinity suggests RSV vaccine sales for older adults could exceed $10B by 2030 in G7 countries. For years, RSV was an...
2023-08-15 10:28:48 ET Icosavax press release ( NASDAQ: ICVX ): Q2 GAAP EPS of -$0.59. Cash and cash equivalents and short-term investments as of June 30, 2023 was $246.9 million, compared to $219.4 million for the period ended December 31, 2022. For further det...
- Positive topline interim Phase 1 results for bivalent VLP vaccine candidate IVX-A12 against RSV and hMPV in older adults - - Positive twelve-month immunogenicity data and initial proof-of-concept for revaccination with IVX-121 against RSV - - Initiation of Phase 2 Trial of IVX...
- In new data from Icosavax’s IVX-121 Phase 1b extension trial in older adults, GMTs against RSV through day 365 persisted at ~45-70% of the GMTs at day 28 (for 75 and 250 µg unadjuvanted dosages) - - Data provide additional clinical evidence of potential differentiation on ...
2023-07-17 07:51:26 ET Summary Icosavax, a US biotech company, is developing vaccines for respiratory viruses using a proprietary virus-like particle technology; its lead product, RSV+hMPV vaccine, could become a multi-billion dollar franchise. The company's IVX-A12 vaccine candid...
2023-07-03 11:27:50 ET Gainers: Ensysce Biosciences ( ENSC ) +28% . Iris Energy Limited ( IREN ) +22% . The Singing Machine Company ( MICS ) +24% . Ventyx Biosciences ( VTYX ) +21% . Barnes & Noble Education ( BNED ) +19% . ...
- Phase 2 topline interim results expected in 1Q 2024 - - 6-month durability data for Phase 1 trial of IVX-A12 also expected in 1Q 2024 - SEATTLE, June 20, 2023 (GLOBE NEWSWIRE) -- Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like...
2023-05-23 12:17:48 ET Shares of Icosavax (NASDAQ: ICVX) were up more than 23% late Tuesday morning after being up as much as 36% earlier in the day. The biotech company, which uses a virus-like particle (VLP) platform to make vaccines to fight infectious diseases, announced positiv...
2023-05-23 10:08:04 ET Gainers: CohBar ( CWBR ) +157% . Ocean Biomedical ( OCEA ) +79% . Shuttle Pharmaceuticals ( SHPH ) +46% . Icosavax ( ICVX ) +31% . Recursion Pharmaceuticals ( RXRX ) +20% . Losers: NantHealth ( ...
News, Short Squeeze, Breakout and More Instantly...
Shandong Weigao Group Medical Polymer Co. Ltd. - Class H (SHWGF) is expected to report for Q4 2023 Country Garden Holdings Co., Ltd. ADR (CTRYY) is expected to report for Q4 2023 Mondi Plc ADR (New) (MONDY) is expected to report for Q4 2023 Telecom Italia S.p.A. ADR - Preference Share...
NEW YORK, NY / ACCESSWIRE / February 1, 2024 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: AVROBIO, Inc. (NASDAQ:AVRO)'s merge...
2024-01-09 00:52:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...